PriceTargets.com logo

Aileron Therapeutics - ALRN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 403.98%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.77 As of 05/17/2024 01:00 AM ET
▼ -0.08 (-2.08%)

This chart shows the closing price for ALRN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aileron Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALRN

Analyst Price Target is $19.00
▲ +403.98% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Aileron Therapeutics in the last 3 months. The average price target is $19.00, with a high forecast of $19.00 and a low forecast of $19.00. The average price target represents a 403.98% upside from the last price of $3.77.

This chart shows the closing price for ALRN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Aileron Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/18/2024LADENBURG THALM/SH SHBoost TargetBuy ➝ Buy$9.00 ➝ $19.00Low
12/1/2023LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$9.00Low
8/1/2022HC WainwrightDowngradeBuy ➝ NeutralLow
6/30/2022HC WainwrightLower TargetBuy$40.00 ➝ $20.00Low
6/29/2022William BlairDowngradeOutperform ➝ Market PerformLow
5/20/2022HC WainwrightReiterated RatingBuy$40.00Low
3/29/2022William BlairReiterated RatingOutperformMedium
3/29/2022HC WainwrightReiterated RatingBuyMedium
11/25/2021JonestradingReiterated RatingBuy$100.00High
5/12/2021HC WainwrightInitiated CoverageBuy$40.00High
3/25/2021HC WainwrightReiterated RatingBuy$40.00Low
8/10/2020William BlairReiterated RatingBuyHigh
8/4/2020HC WainwrightReiterated RatingBuyHigh
6/29/2020HC WainwrightReiterated RatingBuy$40.00High
6/5/2020HC WainwrightLower TargetBuy$60.00 ➝ $40.00Medium
5/11/2020HC WainwrightReiterated RatingBuy$60.00High
4/27/2020HC WainwrightReiterated RatingBuy$60.00High
4/24/2020William BlairReiterated RatingBuyLow
3/31/2020HC WainwrightLower TargetBuy$120.00 ➝ $60.00High
9/30/2019HC WainwrightReiterated RatingBuy$120.00High
9/11/2019HC WainwrightReiterated RatingBuy$120.00High
8/7/2019HC WainwrightReiterated RatingBuy$120.00Medium
(Data available from 5/19/2019 forward)

News Sentiment Rating

0.68 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024
  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2024

Current Sentiment

  • 6 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Aileron Therapeutics logo
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $3.77
Low: $3.70
High: $3.85

50 Day Range

MA: $5.11
Low: $3.65
High: $7.09

52 Week Range

Now: $3.77
Low: $1.01
High: $7.42

Volume

19,489 shs

Average Volume

124,433 shs

Market Capitalization

$81.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Aileron Therapeutics?

The following Wall Street analysts have issued research reports on Aileron Therapeutics in the last twelve months: LADENBURG THALM/SH SH.
View the latest analyst ratings for ALRN.

What is the current price target for Aileron Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Aileron Therapeutics in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 404.0%. LADENBURG THALM/SH SH has the highest price target set, predicting ALRN will reach $19.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $19.00 for Aileron Therapeutics in the next year.
View the latest price targets for ALRN.

What is the current consensus analyst rating for Aileron Therapeutics?

Aileron Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALRN will outperform the market and that investors should add to their positions of Aileron Therapeutics.
View the latest ratings for ALRN.

What other companies compete with Aileron Therapeutics?

Other companies that are similar to Aileron Therapeutics include Viveon Health Acquisition, Lantern Pharma, Mural Oncology, AEON Biopharma and Landos Biopharma. Learn More about companies similar to Aileron Therapeutics.

How do I contact Aileron Therapeutics' investor relations team?

Aileron Therapeutics' physical mailing address is 490 Arsenal Way, Watertown MA, 02472. The company's listed phone number is (617) 995-0900 and its investor relations email address is [email protected]. The official website for Aileron Therapeutics is www.aileronrx.com. Learn More about contacing Aileron Therapeutics investor relations.